Molecular Medicine and Biomedical Research in the Era of Precision Medicine. New Technologies and Personalized Drug Therapies for Patient Care

Table of Contents

Section I: Introduction to molecular medicine, drug discovery and drug delivery, and their roles in biomedical sciences Introduction and Preface

Section II: Technologies in biomedicine and molecular medicine
A: Basic and emerging technologies
1. Single-cell RNA-seq technologies in biomedical studies and their potential clinical applications
2. Next-generation sequencing (NGS), OMICS and gene editing technologies: Their role in biomedical sciences
3. Artificial intelligence in molecular medicine
4. Role of modern scientific technologies and innovations for augmenting health care and precision in health care system
5. Machine Learning in the field of health care using medical images
6. Role of computer assisted prediction models in disease prevention
7. Physiological studies on the usefulness of chips
8. Bioinformatics as a tool for biomedical innovations
9. Molecular Epidemiological approach in disease management
10. Novel aspects of personalized medicines, patient care and management
11. Stem cells and Gene Therapy in disease management
12. Role of telemedicine in point of care treatment of patients

B: Application of technology in some diseases
13. Machine learning based data modeling for heart disease prediction
14. Computational biomedical sciences for renal disease management
15. Impact of machine learning in the prediction and prevention of neurological diseases.
16. Telemedicine and internet-based advice to pregnant and nursing mothers
17. Effectiveness of telemedicine and internet-based diagnosis for the prevention of adverse drug effects (ADRs).
18. Harvesting and growing of stem cells for regenerative medicine with special reference to dermal disorders
19. Nanotechnology innovations for targeted delivery of multiple drugs in cancer patients
20. Development of prolonged drug delivery systems for the treatment of chronic diseases
21. Gold nanoparticles: A promising molecular probe for diagnostic purposes, discovery of new therapies, cure for certain cancers, as well as gene carriers and drug delivery vehicles
22. Impact of circadian rhythms in neurological disorders, cardiovascular diseases, and diabetes mellitus
23. Role of Omics and metabolomics in drug discovery and drug delivery in biomedical sciences
24. Pharmacogenetics in drug dose adjustments in the pediatric and elderly populations
25. Impact of lifestyle factors on cognitive function in older adults (> 60 yrs.) and detection by apolipoprotein E genotyping.

Section III: Interventions and treatments across disease types
A: Role of microbiota in diseases
26. Pivotal role of healthy gut microbiota in the prevention of non-communicable diseases (NCDs)
27. Emerging role of gut microbiomes in immunomodulation and colorectal cancer
28. Influence of the gut microbiomes on cardiovascular health and hypertension
29. Role of probiotics, prebiotics and symbiotic in the improvement of gut microflora
30. Genetic, cellular and molecular biology germane to cardiovascular ailments (e.g., coronary heart disease and stroke) and neurological diseases (e.g., dementia, Alzheimer disease) in the ageing population
31. Molecular biology of chronic heart failure: Prevention and management by antioxidant and anti-inflammation foods and phytotherapies
32. Therapeutic applications of human and bovine colostrum: Underlying mechanisms of action

B: Challenges and interventions in NCDs
33. Environmental impact on cardiorespiratory and kidney related diseases
34. Pathophysiology of coronary heart disease: Role of the renin-angiotensin and aldosterone system
35. Emerging respiratory problems including chronic obstructive pulmonary disease (COPD)
36. Stroke: Causes, diagnosis and management by cholesterol lowering agents and other suitable medicines

C: Challenges and interventions in infectious diseases
37. Emerging and re-emerging infectious diseases and challenges ahead
38. Tuberculosis: Molecular aspects in prediction, diagnosis and treatment
39. Viral hepatitis: its occurrence, diagnosis and management
40. Monkey pox and its impact on human health
41. Prophylactic vaccination strategies for the prevention of microbial diseases with particular reference to COVID-19 on public health and health care system

Section IV: Molecular medicine and nutrition
42. Clinical Nutrition in health promotion and well-being
43. Influence of nutraceuticals in health promotion and disease prevention
44. Biochemical, biophysical and therapeutic properties of functional foods and Mediterranean diet
45. Traditional and novel fermented foods in the prevention of non-communicable diseases (NCDs)
46. Clinical implications and mechanism of drug-drug and drug-food-herbal interactions

???????Section V: Targeted therapies and strategies for the treatment of acute and chronic diseases
47. Emerging trends in drug delivery systems: Scope and challenges
48. Role of Nanotechnology in the targeted delivery of anticancer drugs
49. Impact of Phamacometabolomics in new drug discovery and development of novel therapies for the management of NCDs
50. Drug dose adjustment in elderly population using polypharmacy for co-morbid conditions
51. Safety and efficacy assessment of new vaccines and their development
52. Antibiotic resistance and development alternative therapies
53. Drug regulatory requirements by the drug regulatory agencies
54. Post-marketing surveillance of drugs for monitoring adverse drug reaction (ADRs)
55. Ethical issues and challenges in biomedical research

Section VI: Future perspectives in the development of novel technologies in biomedicine and molecular medicine

Authors

Ranbir Chander Sobti Senior Scientist and Professor Emeritus, Department of Biotechnology, Panjab University, Chandigarh, India. Professor Sobti is an Education Consultant Governor of Bihar and Senior Scientist at the Indian National Science Academy, in addition to Former Vice Chancellor at Babasaheb Bhimrao Ambedkar University, Lucknow, and Panjab University, Chandigarh, India.
Beginning his career as a Cytogeneticist, Professor Sobti moved on to explore the role of gene polymorphisms and their expression in the genesis of various cancers, COPD, AIDS and metabolic syndrome. He has identified disease susceptible / protective novel genotypes and determined the crucial role of SACS-1 and STAT genes in the genesis of cervical and prostate cancers. He has contributed to 270 research publications, 35 books and 23 sponsored research projects. He has received prestigious awards and medals, including the honor of "Padma Shri� from the Government of India for his contribution to higher education. Additionally he was honored with 'Bharat Gaurav', Lifetime Achievement Award at the House of Commons, British Parliament, London, UK. Douglas W Wilson Senior Research Fellow, Centre for Integrated Health Care Research, Queen's Campus, Durham University, UK. Dr Wilson's career has spanned a number of decades and disciplines, from life as a junior chemist to academician at the University of Wales at Aberystwyth and Cardiff where he worked on diet and endocrinology. His early research emphasis was on cancer intervention using epidemiological evidence and related natural and synthetic products which has blossomed into works on phyto-oestrogens and flavonoids many of which form part of his several hundred publications.
Chronomedicine also formed a major part of his work on breast cancer detection using thermorhythmometric procedures.
He has 400-500 publications in biological sciences. In recognition of his contributions to science he has held senior positions in international and national organizations, memberships of many journal boards and is reviewer for many nutritional, statistical and cancer-related journals. He has been an invited global speaker at international events in USA, Asia and Europe and previously Australia and New Zealand. Harpal S Buttar Adjunct Professor, Department of Pathology and Laboratory Medicine University of Ottawa, Faculty of Medicine, Ottawa, Ontario, Canada. Dr. Buttar has made valuable contributions to nanobiotechnology, phytomedicines, functional foods, clinical nutrition and prevention of cardiovascular diseases, obesity, and diabetes. In January 2014, the International Academy of Cardiovascular Sciences (India Section) established the "Dr. Harpal S. Buttar Oration Award" to recognize his leadership and contributions in promoting dietary and lifestyle changes in the prevention of cardiovascular diseases in Canada and around the world.
Based on his scientific accomplishments and distinguished contributions he was awarded Fellowships from the Punjab Academy of Sciences, International College of Nutrition, International Academy of Cardiovascular Sciences, and Indian Society of Pharmaceutical Education and Research. In 2019 the Society for Ethnopharmacology, India, gave the Special Recognition Award to Dr. Buttar for his outstanding contributions made in Phytomedicines and promotion of research in Pharmacology and Pharmaceutical Sciences.
He has authored / co-authored 35 book chapters, one monograph, and 142 research and review papers published in peer-reviewed journals. Istvan G Telessy Associate Professor, Department of Pharmaceutics, Faculty of Pharmacy, University of P�cs, P�cs, Hungary. Dr. T�lessy is a retired associate professor at the University of P�cs (2008) and University of Szeged (2002). He is a specialist in pharmacology and clinical and hospital pharmacy. His main research activity has been in the fields of clinical nutrition and clinical pharmacy. He has published more than 90 papers, written two books (single author) and contributed 6 book chapters.
Dr. T�lessy worked as pharmacist in public pharmacy for 20 years), in the pharmaceutical industry for 18 years and health authority for 5 years.
He is fellow of numerous societies and led the Public Pharmacy Advisory Board of the Minister of Healthcare for 13 years. He was Vice President of the Hungarian Society of Pharmaceutical Sciences and also played a role as lecturer in ESPEN International Expert Courses in Clinical Nutrition for Pharmacy. Aastha Sobti Doctoral student, Department of Immunotechnology, Lund University, Lund, Sweden. Aastha Sobti is a Doctoral student at the Department of Immunotechnology at Lund University, Sweden. Her research areas interests include translational medicine, clinical dentistry, cancer immunology, biomarkers, diagnostics and medical oncology.